Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for RBGLY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for RBGLY and 80,000+ other tickers.
See exactly how RBGLY's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RBGLY and 80,000+ other tickers.
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
UBS, the Swiss investment bank, says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods group, and Haleon, the consumer health group. The bank rates Reckitt 'buy' with a price target of 7,600p, implying 39% upside from its Monday closing price of 5,484p.
A change in Reckitt's sales tactics led to 12 consecutive quarters of double-digit sales growth in the country.
Shares of Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, four have given a buy rating and two have issued
Shares of Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report) gapped up prior to trading on Wednesday. The stock had previously closed at $13.08, but opened at $13.64. Reckitt Benckiser Group shares last traded at $13.5274, with a volume of 23,641 shares traded. Wall Street Analysts Forecast Growth RBGLY has been the topic of
Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer health and hygiene company, faces differing forecasts from UBS and Jefferies ahead of its third-quarter trading update, with both brokers retaining ‘buy' ratings but taking different views on near-term growth. UBS expects group like-for-like sales growth of 3.7% in the third quarter, broadly in line with Visible Alpha consensus, while Core Reckitt is forecast to grow 4.2%, matching the rate reported in the second quarter.